DIRS.INFO The most relevant business & tech news

Dec 5 (Reuters) - Eli Lilly (LLY.N) on Tuesday said its recently approved obesity treatment Zepbound is now available in U.S. pharmacies and could cost $550 a month for customers whose health insurance does not cover the drug, or half the list price. Wall Street analysts expect sales of Zepbound to reach about $2 billion in 2024, and for sales of Novo Nordisk's (NOVOb.CO) rival obesity drug Wegovy to hit around $7.5 billion. An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. When the U.S. Food and Drug Administration approved Zepbound in November, Lilly said it would launch after the U.S. Thanksgiving holiday. Lilly's obesity drug has the same active ingredient, tirzepatide, as its previously approved diabetes drug Mounjaro, which has been used off-label for weight loss since its 2022 launch.

Persons: Eli Lilly, Wegovy, danuglipron, Zepbound, Lilly, Mike Segar, Eli Lilly's, Patrick Wingrove, Manas Mishra, Khushi, Arun Koyyur, Alexander Smith, Bill Berkrot Organizations: Wall Street, Novo, Pfizer, Company, REUTERS, CVS, U.S . Food, Drug Administration, U.S, Thomson Locations: U.S, Branchburg , New Jersey, Indianapolis, New York, Bengaluru

☆ Pfizer drops plan to study twice-daily obesity pill in late-stage studies
▼ + stars: | 2023-12-01 | by ( ) www.reuters.com time to read: +2 min

A person walks past the Pfizer Headquarters building in the Manhattan borough of New York City, New York, U.S., November 9, 2020. Pfizer said it would instead focus on a once-daily, modified release version of danuglipron and "gathering the data to understand its potential profile". In the current study of the twice-daily version, Pfizer said the drug, however, met the main goal of reducing weight in adults with obesity and without type 2 diabetes. Pfizer said while the common side effects in the twice-daily version study were mild, it saw high rates of those events in the trial. However, no new safety signals were observed in the study, Pfizer said.

Persons: Carlo Allegri, danuglipron, Eli Lilly's, Mikael Dolsten, Pfizer, Manas Mishra, Michael Erman, Shinjini Organizations: Pfizer, REUTERS, Zepbound, Thomson Locations: Manhattan, New York City , New York, U.S, Bengaluru, New York

☆ AbbVie to buy cancer drugmaker ImmunoGen for $10 billion as Humira faces heat
▼ + stars: | 2023-11-30 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Brian Snyder/File Photo Acquire Licensing RightsNov 30 (Reuters) - AbbVie (ABBV.N) will buy ImmunoGen (IMGN.O) for $10.1 billion in cash, it said on Thursday, the latest major drugmaker to buy a developer of 'guided missile' cancer therapies as the company's top-seller Humira grapples with fierce competition. ImmunoGen's Elahere belongs to a new class of treatments called antibody-drug conjugates (ADC) that precisely targets cancer cells, potentially reducing toxicity for other cells. The drug, approved for ovarian cancer patients who have received previous therapies, is also being tested in earlier lines of treatment. AbbVie will also get access to Immunogen's follow-on pipeline of ADCs, including early-stage ovarian cancer candidate IMGN-151 and a mid-stage drug pivekimab sunirine for a rare type of blood cancer. Meanwhile, AbbVie's cancer drugs sales declined more than 8% in the third quarter to $1.51 billion, primarily due to increased competition to Imbruvica.

Persons: Brian Snyder, ImmunoGen's Elahere, AbbVie, IMGN, pivekimab, Immuogen stock's, Immunogen's, Elahere, Imbruvica, Manas Mishra, Leroy Leo, Shinjini Ganguli Organizations: REUTERS, Pfizer, Merck, U.S, Thomson Locations: Cambridge , Massachusetts, U.S, Bengaluru

☆ US health insurers Humana, Cigna in talks to merge - WSJ
▼ + stars: | 2023-11-29 | by ( ) www.reuters.com time to read: +1 min

[1/2] Signage for Humana Inc. is pictured at a health facility in Queens, New York City, U.S., November 30, 2021. REUTERS/Andrew Kelly/File Photo Acquire Licensing RightsNov 29 (Reuters) - Health insurers Cigna (CI.N) and Humana (HUM.N) are in talks for a merger, the Wall Street Journal reported on Wednesday, citing people familiar with the matter. Cigna's shares were down 4.4% in noon trading, while Humana's stock was flat. The companies did not immediately respond to Reuters requests for comment. Reporting by Manas Mishra in Bengaluru; Editing by Sriraj KalluvilaOur Standards: The Thomson Reuters Trust Principles.

Persons: Andrew Kelly, Cigna, Manas Mishra, Sriraj Organizations: Humana Inc, REUTERS, Health, Cigna, Wall Street, Thomson Locations: Queens , New York City, U.S, Bengaluru

REUTERS/Andrew Kelly/File Photo Acquire Licensing RightsNov 29 (Reuters) - Cigna (CI.N) and Humana (HUM.N), two of the biggest U.S. health insurers, are in talks for what could be the largest merger announced in 2023, according to a source familiar with the matter. A Humana and Cigna combination would give the merged company the scale to rival UnitedHealth Group (UNH.N) and CVS Health (CVS.N). In July 2016, the Justice Department filed lawsuits against two health insurance mergers on the same day, saying they would lead to less competition and higher prices for Americans. Health insurers have been facing higher medical costs as people return for procedures they had put off during the pandemic. Humana in February said that it would sell its commercial business but keep its Medicare Advantage products.

Persons: Andrew Kelly, Cigna, Cigna's, Aetna, Bill Baer, Andre Barlow of Doyle, Barlow, Mazard, Bernstein, Lance Wilkes, Craig Garthwaite, Manas Mishra, Diane Bartz, Deena Beasley, Caroline Humer, Bill Berkrot Organizations: Humana Inc, REUTERS, Street Journal, UnitedHealth, CVS Health, Humana’s, Medicare, Affordable, Justice Department, Humana, U.S ., Reuters, Northwestern University, Thomson Locations: Queens , New York City, U.S, Cigna, Bengaluru, Washington, Los Angeles

Nov 8 (Reuters) - NuScale Power (SMR.N) said on Wednesday it has agreed with a power group in Utah to terminate the company's small modular reactor project, dealing a blow to U.S. ambitions for a wave of nuclear energy to fight climate change and sending NuScale's shares down 20%. In 2020, the Department of Energy approved $1.35 billion over 10 years for the plant, known as the Carbon Free Power Project, subject to congressional appropriations. NuScale's Utah plant was expected to be the first SMR to win a license from the U.S. Nuclear Regulatory Commission for construction. An Energy Department spokesperson said it was unfortunate news, but added, "We believe the work accomplished to date on CFPP will be valuable for future nuclear energy projects. So far, only NuScale's SMR design has been approved by the NRC.

Persons: NuScale, John Hopkins, Critics, Biden, Manas Mishra, Timothy Gardner, Shounak Dasgupta, Krishna Chandra Eluri, Leslie Adler Organizations: Department of Energy, Carbon, Power, Utah Associated Municipal Power Systems, SMR, U.S . Nuclear Regulatory Commission, Energy Department, DOE, NRC, Thomson Locations: Utah, Romania, Kazakhstan, Poland, Ukraine, NuScale's Utah, U.S, Bengaluru, Washington

☆ FTC seeks information on $8.5 bln Tapestry-Capri deal
▼ + stars: | 2023-11-06 | by ( ) www.reuters.com time to read: +1 min

The logo of Michael Kors is seen on an outlet store in Metzingen, Germany, June 16, 2017. REUTERS/Michaela Rehle/File Photo Acquire Licensing RightsNov 6 (Reuters) - The U.S. Federal Trade Commission (FTC) has sent requests to Tapestry (TPR.N) and Michael Kors owner Capri Holdings (CPRI.N) for more information on their planned $8.5 billion deal, the companies said on Monday. The companies said on Monday they expect to respond "promptly" to the FTC's request and aim to close the deal as planned, in 2024. Capri's shares, which had jumped 55% on Aug. 10 after the deal was announced, were down 2.5% in extended trade. Reporting by Manas Mishra and Juveria Tabassum in Bengaluru; Editing by Shounak Dasgupta and Krishna Chandra EluriOur Standards: The Thomson Reuters Trust Principles.

Persons: Michael Kors, Michaela Rehle, Kate Spade, Stuart Weitzman, Jimmy Choo, Versace, Capri's, Tapestry, Manas Mishra, Juveria, Shounak Dasgupta, Krishna Chandra Organizations: REUTERS, U.S . Federal Trade Commission, Capri Holdings, Capri, Thomson Locations: Metzingen, Germany, Paris, Bengaluru

☆ Unlike Pfizer, Moderna can meet 2023 COVID forecast, analysts say
▼ + stars: | 2023-11-01 | by ( Khushi Mandowara | ) www.reuters.com time to read: +3 min

Syringes with needles are seen in front of a displayed Moderna logo in this illustration taken, November 27, 2021. Around 20 million people need to be vaccinated with Moderna's updated COVID-19 vaccine for the company to reach $2 billion in 2023 sales from the private market, a figure four analysts told Reuters was achievable. The company has said it expects total U.S. COVID vaccine demand to be as much as 100 million doses in the fall season. Moderna forecast $6 billion to $8 billion for sales of its COVID-19 vaccine in 2023, $2 billion to $4 billion of which is expected to come from the commercial market. The COVID vaccine is Cambridge, Massachusetts-based Moderna's lone marketed product.

Persons: Dado Ruvic, Oppenheimer, Hartaj Singh, Michael Yee, Yee, Manas Mishra, Khushi, Patrick Wingrove, Bill Berkrot Organizations: REUTERS, Reuters, U.S, Moderna, Pfizer, Jefferies, GSK, Thomson Locations: Cambridge , Massachusetts, United States, Bengaluru, New

☆ WeWork plans to file for bankruptcy as early as next week, source says
▼ + stars: | 2023-10-31 | by ( ) www.reuters.com time to read: +2 min

[1/3] WeWork logos are seen at a WeWork office in San Francisco, California, U.S. September 30, 2019. REUTERS/Kate Munsch Acquire Licensing RightsOct 31 (Reuters) - WeWork (WE.N) plans to file for bankruptcy as early as next week, a source familiar with the matter said on Tuesday, as the SoftBank Group-backed company struggles with a massive debt pile and hefty losses. Shares of the flexible workspace provider fell 32% in extended trading after the Wall Street Journal first reported the news. New York-based WeWork is considering filing a Chapter 11 petition in New Jersey, the WSJ reported, citing people familiar with the matter. Its major backer, Japanese conglomerate SoftBank, sunk tens of billions to prop up the startup, but the company has continued to lose money.

Persons: Kate Munsch, WeWork, Sandeep Mathrani, Anirban Sen, Manas Mishra, Manya, Shailesh Kuber, Anil D'Silva Organizations: REUTERS, SoftBank, Wall Street Journal, WSJ, Manya Saini, Thomson Locations: San Francisco , California, U.S, New York, New Jersey, Bengaluru

Such forecasts have prompted a sell-off in a wide range of companies from makers of bariatric surgery devices to companies whose products address the health issues created by excess weight, from diabetes to sleep apnea. "The market is in a shoot-first, ask-questions-later mood when it comes to weight-loss drugs," said Nicholas Anderson, manager of the Thornburg International Growth Fund, which holds shares of Novo Nordisk. By contrast, the iShares U.S. Medical Devices exchange-traded fund has lost more than 22% in the last three months. Injectable weight-loss drugs, known as GLP-1 receptor agonists, are considered highly effective but are also expensive, costing more than $1,300 per month. "Overall, we'll see an increased interest in bariatric surgery, but that will get delayed in the short term."

Persons: Doctor Thomas Horbach, Wegovy, Nicholas Anderson, Eli Lilly, Kenneth Stein, Margaret Kaczor Andrew, William Blair, Michael Farrell, Jeff Jonas, Johnson, Myriam Curet, Ann Hynes, Hynes, David Gaffen, Manas, Michael Erman, Caroline Humer, Sonali Paul Organizations: Novo Nordisk, Healthcare, Growth Fund, Medical Devices, Boston, Gabelli Funds, Johnson, Reuters, Mizuho Securities, Manas Mishra, Thomson Locations: Germany, Munich, Danish, U.S, Boston, GLP, New York, Bengaluru

☆ Pfizer, BioNTech shares fall on lower COVID product sales forecast
▼ + stars: | 2023-10-16 | by ( Ludwig Burger | ) www.reuters.com time to read: +2 min

REUTERS/Dado Ruvic/File photo Acquire Licensing RightsOct 16 (Reuters) - Shares of Pfizer (PFE.N) and German partner BioNTech (22UAy.DE) fell on Monday after the U.S. drugmaker slashed the sales forecast for its COVID vaccine and therapy last week, and some analysts said the reduction was bigger than expectations. The COVID sales forecast cut was bigger than expected, Wells Fargo analyst Mohit Bansal said, adding that Wall Street's COVID sales estimates for the next few years may come down. Shares in BioNTech, which is also developing cancer treatments, were down 6.7% at a two-month low in Frankfurt. Its U.S.-listed shares fell 6.8% in premarket trading, while Pfizer's shares fell 2%. The news also dragged down shares of rival COVID vaccine maker Moderna (MRNA.O) by 4.7%.

Persons: Dado, BioNTech, drugmaker, Wells, Mohit Bansal, Ludwig Burger, Rachel More, Miranda Murray, Jason Neely, Shounak Organizations: COVID, Institute for Health, Food, REUTERS, Pfizer, U.S, Its U.S, Moderna, Manas Mishra, Thomson Locations: Zenica, Bosnia, Herzegovina, Wells Fargo, BioNTech, Frankfurt, Its, Bengaluru

Vaccine makers are depending on the U.S. market as many countries have more limited yearly campaigns for giving updated shots. For BioNTech, Moderna, and Novavax (NVAX.O), COVID vaccines remain their only approved products. Shares of Pfizer were up nearly 5%, however, buoyed by a $3.5 billion cost-cutting plan the drugmaker announced late on Friday alongside its new COVID sales outlook. Moderna, in a statement on Monday, maintained its current revenue forecast of $6 billion to $8 billion for its COVID vaccine for 2023. Jefferies analyst Michael Yee said Pfizer's new COVID outlook implies lower vaccine sales for Moderna than it had forecast.

Persons: Dado, BioNTech, Albert Bourla, Bourla, Mani Foroohar, Foroohar, Jefferies, Michael Yee, Ludwig Burger, Rachel More, Michael Erman, Bhanvi Satija, Manas, Jonathan Oatis, Caroline Humer, Bill Berkrot Organizations: COVID, Institute for Health, Food, REUTERS, Pfizer, Moderna, Manas Mishra, Thomson Locations: Zenica, Bosnia, Herzegovina, Frankfurt, Novavax, U.S, New York, Bengaluru

Oct 13 (Reuters) - A union coalition for Kaiser Permanente healthcare workers reached a tentative labor deal with the hospital system on Friday that included across-the-board wage increases after 75,000 members took part in a three-day strike last week. The strike was the largest recorded among medical workers and included nurses, medical technicians and support staff at hundreds of Kaiser hospitals and clinics from California to Virginia. "I’m heartened to see healthcare workers and their employers take this critical step towards securing the pay, benefits, and working conditions these heroes deserve," President Joe Biden said in a statement. The Kaiser union coalition had threatened to strike again for a week starting Nov. 1. The union had said Kaiser would need to hire 10,000 new healthcare workers to fill current vacancies.

Persons: Julie Su, Biden, Joe Biden, Kaiser, Su, Manas Mishra, Leroy Leo, Steve Gorman, Arun Koyyur, Shinjini, Maju Samuel, Jonathan Oatis Organizations: Kaiser Permanente, Labor, Tenet Healthcare, District of Columbia, Writers Guild of America, United Auto Workers, Detroit, Thomson Locations: California, Virginia, San Francisco Bay, Bengaluru, Los Angeles

☆ Kaiser Permanente, union reach tentative agreement after biggest healthcare strike
▼ + stars: | 2023-10-13 | by ( ) www.reuters.com time to read: +2 min

"We are excited to have reached a tentative agreement with the frontline health care workers of the @UnionCoalition this morning," Kaiser Permanente said on social media platform X. Kaiser Permanente and its coalition of healthcare workers unions did not immediately respond to requests for details on the agreement. The unions had said Kaiser outsourcing healthcare duties to third-party vendors and subcontactors also was a major sticking point in talks that have dragged on for six months. Company and union spokespersons had said on Thursday the two sides met in person late in the day at a San Francisco Bay-area hotel. "We are thankful for the instrumental involvement of Acting U.S. Labor Secretary," Kaiser said on X.

Persons: Kaiser, Kaiser Permanente, subcontactors, Julie Su, Manas Mishra, Leroy Leo, Steve Gorman, Shounak Dasgupta, Sriraj Organizations: Kaiser Permanente, Labor, U.S, Unions, U.S . Bureau of Labor Statistics, Thomson Locations: U.S, San Francisco Bay, Bengaluru, Los Angeles

☆ Kaiser Permanente, workers union reach tentative agreement
▼ + stars: | 2023-10-13 | by ( ) www.reuters.com time to read: +2 min

Oct 13 (Reuters) - Kaiser Permanente's healthcare workers union has reached a tentative deal with the company, the union said in a social media post on Friday, moving toward settling a dispute over staffing levels and pay that sparked the largest strike in the U.S. medical sector. Terms of the agreement were not immediately disclosed, but higher pay and increased hiring to address what union officials called crisis-level staffing shortages topped the workers' list of demands. The company has acknowledged staffing shortages plaguing the entire healthcare sector, a consequence of occupational "burnout" from the pandemic, leading to more than 5 million medical workers leaving their jobs. Kaiser Permanente and its coalition of healthcare workers unions did not immediately respond to Reuters' request for details on the agreement. Company and union spokespersons had said on Thursday the two sides met in person late in the day at a San Francisco Bay-area hotel.

Persons: Julie Su, Manas Mishra, Leroy Leo, Shounak Dasgupta Organizations: Kaiser Permanente, Reuters, Union, Kaiser, . Company, Labor, Unions, U.S . Bureau of Labor Statistics, Thomson Locations: U.S, San Francisco Bay, Bengaluru

Oct 13 (Reuters) - Kaiser Permanente's frontline healthcare workers union reached a tentative deal with the company on Friday, moving toward settling a payment and staffing dispute that had sparked the largest recorded strike in the U.S. medical sector. The strike by 75,000 workers last week had put Kaiser at the forefront of a growing labor unrest in the healthcare industry, including among employees of pharmacies and other hospital chains like Tenet Healthcare (THC.N). "What they've achieved here in Oakland (San Francisco Bay Area) is great news for frontline workers, for Kaiser and the patients in their collective care," Su said. Spokespersons for Kaiser Permanente and its coalition of healthcare workers unions said they would provide further details on the agreement later in the day. Kaiser is one of the largest U.S. medical employers with 24,000 doctors, 68,000 nurses, 213,000 technicians, clerical workers and administrative staff.

Persons: Kaiser, Julie Su, Su, Kaiser Permanente, Manas Mishra, Leroy Leo, Steve Gorman, Shounak Dasgupta, Sriraj Kalluvila, Arun Koyyur Organizations: Tenet Healthcare, Labor, Kaiser Permanente, District of Columbia, United Auto Workers, Detroit, U.S . Bureau of Labor Statistics, Thomson Locations: U.S, San Francisco Bay, Oakland, Bengaluru, Los Angeles

☆ Maker of MDMA-assisted PTSD treatment to seek US regulatory nod
▼ + stars: | 2023-09-15 | by ( ) www.reuters.com time to read: +2 min

A woman retrieves items from the rubble of her destroyed home after a wildfire came through the area in Talent, Oregon, Oregon, U.S. September 21, 2020. PTSD is a disorder caused by very stressful events and can significantly disrupt patients' lives. While PTSD is commonly associated with combat, civilians are not immune to it. Psychoactive ingredients, whether derived from cannabis, LSD or magic mushrooms, have long captivated mental health researchers in their quest for treatments. MAPS, founded in 1986, said it hopes the MDMA-assisted therapy will be approved next year and inspire other researchers studying therapeutic psychedelics.

Persons: Jim Urquhart, Manas Mishra, Pooja Desai Organizations: REUTERS, Multidisciplinary Association for Psychedelic Studies, U.S . Food, Drug Administration, Thomson Locations: Talent , Oregon , Oregon, U.S, United States, Bengaluru

An Amgen sign is seen at the company's office in South San Francisco, California in this October 21, 2013. Under the FTC settlement, Amgen is prohibited from bundling any of its products with Tepezza or Krystexxa, and from using any product rebate or contract term to exclude or disadvantage products that would compete with those drugs. It also prevents Amgen from buying any competitors to the two Horizon drugs without the FTC's permission. The lawsuit had raised concerns over increased oversight on mergers and acquisitions in a sector that often turns to consolidation to power future growth as patents on older treatments expire. Shares of Seagen Inc (SGEN.O), which is in the process of being acquired by Pfizer (PFE.N), rose 1.5%.

Persons: Robert Galbraith, Lina Khan, Robyn Karnauskus, Khan, Manas Mishra, David Shepardson, Devika Organizations: REUTERS, U.S . Federal Trade Commission, Horizon Therapeutics, FTC, Seagen Inc, Pfizer, Thomson Locations: South San Francisco , California, Amgen, Bengaluru, Washington

☆ Walgreens CEO Brewer steps down less than three years into job
▼ + stars: | 2023-09-01 | by ( ) www.reuters.com time to read: +2 min

Pigeons are seen resting on signage for Walgreens, owned by the Walgreens Boots Alliance, Inc., in Manhattan, New York City, U.S., November 26, 2021. REUTERS/Andrew Kelly/File Photo Acquire Licensing RightsSept 1 (Reuters) - Walgreens Boots Alliance (WBA.O) said on Friday CEO Rosalind Brewer has stepped down less than three years since she took the top job at the pharmacy chain operator. The company's board and Brewer had mutually agreed that she would step down, Walgreens said, without providing further details. Brewer, a former Starbucks (SBUX.O) executive, joined Walgreens in 2021. Walgreens' shares have lost about 47% of their value since March 2021, when Brewer became CEO.

Persons: Andrew Kelly, Rosalind Brewer, Brewer, Ginger Graham, Manas Mishra, Shounak Dasgupta Organizations: Walgreens, Walgreens Boots Alliance, Inc, REUTERS, Starbucks, Thomson Locations: Manhattan , New York City, U.S, COVID, Bengaluru

☆ J&J, India's Lupin cut prices for tuberculosis drug in lower-income countries
▼ + stars: | 2023-08-30 | by ( ) www.reuters.com time to read: +2 min

FILE PHOTO-The Johnson & Johnson logo is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., May 29, 2019. The drug will be available at the lower prices through the Stop TB Partnership's Global Drug Facility, which is the largest procurer of TB treatments. J&J, which sells bedaquiline under the brand name Sirturo, reached an agreement with the Stop TB Partnership in July to allow the coalition to supply generic versions of the drug through the Global Drug Facility. J&J has said it is false to suggest its patents prevent access to the drug. But J&J could further increase access to the drug by withdrawing its secondary patents on bedaquiline in all high-burden countries, said Christophe Perrin, TB advocacy pharmacist with MSF's Access Campaign.

Persons: Johnson, Brendan McDermid, bedaquiline, Atul Gawande, John Green, Médecins, Christophe Perrin, Manas Mishra, Devika Organizations: New York Stock Exchange, REUTERS, Johnson, United Nations, TB, United States Agency, International Development's Global Health Bureau, Drug Facility, Global Drug, Thomson Locations: New York, U.S, Bengaluru

☆ J&J forecasts 12.5% growth in 2023 profit after Kenvue spinoff
▼ + stars: | 2023-08-30 | by ( ) www.reuters.com time to read: +1 min

Johnson & Johnson company offices are shown in Irvine, California, U.S., October 14, 2020. REUTERS/Mike Blake Acquire Licensing RightsAug 30 (Reuters) - Johnson & Johnson (JNJ.N) on Wednesday forecast 12.5% growth in its annual adjusted profit after completing the separation of consumer health company Kenvue (KVUE.N) . J&J also said it would present its consumer health business as discontinued operations and record a gain of $20 billion in the third quarter as a result of the spinoff. It expects 2023 adjusted reported earnings per share of $10.00 - $10.10, 12.5% higher at the midpoint compared with 2022. Kenvue, which debuted on the New York Stock Exchange in May, has a market capitalization of about $78.9 billion.

Persons: Johnson, Mike Blake, J, Kenvue, Manas Mishra, Devika Organizations: Johnson, REUTERS, New York Stock Exchange, Thomson Locations: Irvine , California, U.S, Bengaluru

[1/2] A pharmacist holds a bottle of the drug Eliquis, sold by Bristol Myers Sqibb and Pfizer at a pharmacy in Provo, Utah, U.S. January 9, 2020. REUTERS/George Frey/File Photo Acquire Licensing RightsAug 29 (Reuters) - The U.S. government on Tuesday selected the first 10 drugs, including the big-selling blood thinner Eliquis from Bristol Myers Squibb (BMY.N) and Pfizer (PFE.N) , that will be subject to the first-ever Medicare price negotiations, part of President Joe Biden’s Inflation Reduction Act (IRA) that drugmakers and industry groups have challenged in court. At least eight lawsuits were filed between June and late August seeking to block the price negotiation, arguing that the law and forced price cuts would violate various amendments to the U.S. constitution. The following are key details of the lawsuits:Reporting by Manas Mishra and Sriparna Roy in Bengaluru; Editing by Bill BerkrotOur Standards: The Thomson Reuters Trust Principles.

Persons: Bristol Myers Sqibb, George Frey, Joe Biden’s, Manas Mishra, Sriparna Roy, Bill Berkrot Organizations: Bristol, Pfizer, REUTERS, U.S, Bristol Myers Squibb, Thomson Locations: Provo , Utah, U.S, Bengaluru

He said that once implemented, the prices on negotiated drugs will decrease for up to 9 million seniors who currently pay as much as $6,497 in out-of-pocket costs per year for these prescriptions. This kicks off the negotiation process for the 10 drugs whose new prices will go into effect in 2026. U.S. laws had prohibited Medicare from negotiating pharmaceutical prices as part of its prescription drug program that began about 20 years ago. CMS Director Dr. Meena Seshamani said Medicare plans to use a review process to make sure insurance companies keep clinically appropriate access to negotiated drugs. Two analysts said they expect the negotiated prices to move beyond Medicare and affect commercial markets for these drugs by 2026, when they come into effect.

Persons: Joe Biden, Jonathan Ernst, Biden, Joe Biden’s, Januvia, Xarelto, Johnson, Boehringer Ingelheim, Eli Lilly's, Jardiance, Mohit Bansal, Entresto, Eli Lilly, Merck, Bristol Myers, Giovanni Caforio, Caforio, enrollees, Meena Seshamani, Stelara, Amgen, Evan Seigerman, Patrick Wingrove, Mike Erman, Manas Mishra, Nandita Bose, Caroline Humer, Bill Berkrot Organizations: Social Security, University of Tampa, REUTERS, U.S, Bristol Myers Squibb, Pfizer, Merck, Co's, Johnson, Novo Nordisk, NYSE Arca Pharmaceutical, U.S . Centers, Medicare, Medicaid Services, Reuters Graphics Wells, Novartis, AstraZeneca, Bristol, J, U.S . Department of Health, Human Services, BMO Capital, Thomson Locations: Tampa , Florida, U.S, Amgen's, Jardiance, Germany, Bengaluru, Washington

☆ Medical tech firm Danaher to buy Abcam in $5.7 bln deal
▼ + stars: | 2023-08-28 | by ( ) www.reuters.com time to read: +2 min

Aug 28 (Reuters) - Danaher Corp (DHR.N) said on Monday it would buy smaller rival Abcam Plc in an all-cash deal valued at $5.7 billion including debt, as the medical tools supplier expands its services to capture bigger contracts. The deal will help Danaher cushion the hit from sluggish demand for its products such as antibodies and sample preparation equipment from smaller biotech companies that are grappling with a funding crunch. Danaher, one of the world's largest suppliers of medical tools, has already cut its annual sales growth forecast multiple times this year. "This is a nice tuck in deal for Danaher that checks all the boxes. Reuters reported on Friday that Danaher was in the lead to acquire Abcam.

Persons: Vijay Kumar, Danaher, Jonathan Milner, Manas Mishra, Shounak Dasgupta, Sriraj Organizations: Danaher, Abcam Plc, Reuters, Bloomberg, Electric, Thomson Locations: Cambridge, England, Bengaluru

CVS Health logo is seen displayed in this illustration taken, May 3, 2022. The regional health insurance provider will still retain CVS Caremark for managing specialty drugs, which are costly medications used to treat complex conditions like cancer and rheumatoid arthritis. Other analysts highlighted difficulties in shifting to a different model than the one offered by companies like CVS - which provide other services including home drug delivery and reimburse pharmacies for patients' prescriptions. Amazon Pharmacy will provide at-home delivery of prescription drugs as well as upfront pricing, while Mark Cuban Cost Plus Drug Company will provide access to generic drugs, Blue Shield said. Blue Shield of California's other partners include privately held Abarca for processing claims related to prescription drugs, while smaller PBM Prime Therapeutics will work to negotiate savings with drugmakers.

Persons: Dado Ruvic, Cigna, UnitedHealth, Mark, Elizabeth Anderson, J.P, Morgan, Lisa Gill, Gill, Blue, Manas Mishra, Mariam Sunny, Bhanvi, Shweta Agarwal, Pooja Desai, Krishna Chandra Eluri, Frances Kerry Organizations: CVS, REUTERS, Amazon, Cigna, UnitedHealth, Evercore ISI, Mark Cuban, Plus, Thomson Locations: Bengaluru

Search resuls for: "Manas Mishra"

25 mentions found